A protective effect of rimonabant—a synthetic CB1 antagonist—on obesity-associated hepatic steatosis has been shown in rats,43 and on hepatic fat infiltration in severely uncontrolled diabetic rats.44 Positive effects have also been obtained in humans.45,46 However, rimonabant was quickly withdrawn because of serious psychiatric side effects,47 thereby contributing to reduce the interest in using cannabinoids as treatment for metabolic disorders. This evidence concerns the gene CNR1 and fatty liver disease.